Compare PCVX & JBTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCVX | JBTM |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.9B |
| IPO Year | 2020 | 2008 |
| Metric | PCVX | JBTM |
|---|---|---|
| Price | $56.05 | $106.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $109.00 | ★ $167.06 |
| AVG Volume (30 Days) | ★ 1.2M | 436.9K |
| Earning Date | 11-03-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 0.38% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.40 |
| Revenue | N/A | ★ $3,798,200,000.00 |
| Revenue This Year | N/A | $5.89 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | ★ N/A | $78.88 |
| Revenue Growth | N/A | ★ 121.34 |
| 52 Week Low | $39.87 | $109.55 |
| 52 Week High | $65.00 | $170.19 |
| Indicator | PCVX | JBTM |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 30.01 |
| Support Level | $52.18 | N/A |
| Resistance Level | $58.77 | $114.74 |
| Average True Range (ATR) | 2.19 | 2.63 |
| MACD | -0.27 | -0.13 |
| Stochastic Oscillator | 30.24 | 12.10 |
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
JBT Marel Corp operates through two reportable segments: Protein Solutions and Prepared Food and Beverage Solutions. The Protein Solutions segment includes businesses that provide solutions for the initial stage processing and harvesting of animal proteins, mainly focusing on poultry, pork, fish, and beef. The Prepared Food and Beverage Solutions segment includes businesses that offer solutions predominantly for downstream value-added preparation, preservation, and packaging of foods and beverages into ready-to-eat or drink products. This segment will also include capabilities for pet food, dairy, bakery, pharmaceutical, nutraceutical, and warehouse automation end markets. The majority of its revenue is generated from the Prepared Food and Beverage Solutions segment.